A CD90(+) Tumor-initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer
Overview
Authors
Affiliations
Tumor-initiating cells (TIC), also known as cancer stem cells, are regarded widely as a specific subpopulation of cells needed for cancer initiation and progression. TICs have yet to be identified in esophageal tumors that have an increasing incidence in developed countries. Here, we report a CD90(+) cell population found in esophageal squamous cell carcinoma (ESCC), which is endowed with stem cell-like properties and high tumorigenic and metastatic potential. mRNA profiling of these cells suggested pathways through which they drive tumor growth and metastasis, with deregulation of an Ets-1/MMP signaling pathway and epithelial-mesenchymal transition figuring prominently. These cells possessed higher self-renewal activity and were sufficient for tumor growth, differentiation, metastasis, and chemotherapeutic resistance. CD90(+) TICs were isolated and characterized from ESCC clinical specimens as well as ESCC cell lines. In freshly resected clinical specimens, they represented a rare cell population, the levels of which correlated with strong family histories and lymph node metastasis. Our results prompt further study of this CD90(+) population of esophageal TICs as potential therapeutic targets.
Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy.
Choudhury A, Cady M, Lucas C, Najem H, Phillips J, Palikuqi B Cancer Discov. 2024; 14(10):1823-1837.
PMID: 38742767 PMC: 11452293. DOI: 10.1158/2159-8290.CD-23-1459.
Potential markers of cancer stem-like cells in ESCC: a review of the current knowledge.
Wang L, Liu H, Liu Y, Guo S, Yan Z, Chen G Front Oncol. 2024; 13:1324819.
PMID: 38239657 PMC: 10795532. DOI: 10.3389/fonc.2023.1324819.
Cancer stem cells: a target for overcoming therapeutic resistance and relapse.
Zhang S, Yang R, Ouyang Y, Shen Y, Hu L, Xu C Cancer Biol Med. 2024; .
PMID: 38164743 PMC: 10845928. DOI: 10.20892/j.issn.2095-3941.2023.0333.
Lv M, Gong Y, Liu X, Wang Y, Wu Q, Chen J Signal Transduct Target Ther. 2023; 8(1):302.
PMID: 37582812 PMC: 10427695. DOI: 10.1038/s41392-023-01555-9.
Chen L, Chau W, Yuen H, Liu X, Qi R, Lung M Cancers (Basel). 2023; 15(7).
PMID: 37046850 PMC: 10093038. DOI: 10.3390/cancers15072189.